Antipsychotic agents in the treatment of anorexia nervosa: Neuropsychopharmacologic rationale and evidence from controlled trials

Current Psychiatry Reports

Volumn 14, Issue 4, 2012, Pages 398-405

  Brewerton, Timothy D ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE   (United States)

Author keywords

5 HT receptors; AN; Anorexia nervosa; Antipsychotics; Aripiprazole; Behavior therapy; Chlorpromazine; Cognitive behavioral therapy; DA receptors; Delusions; Dopamine; Eating disorders; Genetics; Neurophysiology; Neuropsychopharmacology; Olanzapine; Pimozide; Quetiapine; Risperidone; Serotonin; Sulpiride; Treatment

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; DOPAMINE; OLANZAPINE; PIMOZIDE; PLACEBO; RISPERIDONE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SULPIRIDE;

ANOREXIA NERVOSA; ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; BULIMIA; COGNITIVE THERAPY; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DOPAMINERGIC SYSTEM; DRUG DOSE TITRATION; HEALTH BELIEF; HUMAN; MAJOR DEPRESSION; NEUROBIOLOGY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHENOMENOLOGY; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; SEROTONINERGIC SYSTEM;

EID: 84865659617     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0287-6     Document Type: Article

References (55)

1. Bruch H. Eating disorders: Obesity, anorexia nervosa, and the person within. Houston: Basic Books; 1973.
2. Steinglass JE, Eisen JL, Attia E, et al. Is anorexia nervosa a delusional disorder? An assessment of eating beliefs in anorexia nervosa. J Psychiatr Prac. 2007;13:65-71. (Pubitemid 46588307)
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington: American Psychiatric Association; 1994.
4. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359-69.
5. McElroy SL, Kotwal R, Keck Jr. PE, Akiskal HS. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Dis. 2005;86:107-27. (Pubitemid 40789945)
6. McElroy SL, Kotwal R, Keck Jr. PE. Comorbidity of eating disorders with bipolar disorder and treatment implications. Bipolar Dis. 2006;8:686-95. (Pubitemid 44824709)
7. Wildes JE, Marcus MD, Fagiolini A. Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder. Psychiatry Res. 2008;161:51-8.
8. Wang TS, Chou YH, Shiah IS. Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Prog Neuro-Psychopharm Biol Psychiatry. 2006;30:306-9.
9. Attia E, Mayer L, Killory E. Medication response in the treatment of patients with anorexia nervosa. J Psychiatr Pract. 2001;7:157-62.
10. Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. JAMA. 2006;295:2605-12. (Pubitemid 43882335)
11. Brewerton TD. Drug therapy for patients with eating disorders. Psychiatric Times. 2004;21:59-68.
12. Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinol. 1995;20:561-90.
13. Brewerton TD. Transmitter systems in the eating disorders. In: D'haenen H, den Boer JA, Westenberg H, Willner P (ed) Textbook of biological psychiatry. New York: Wiley; 2002.
14. Brewerton TD, Steiger H. Neurotransmitter dysregulation in anorexia nervosa, bulimia nervosa and binge eating disorder. In: Brewerton TD, editor. Clinical handbook of eating disorders: An integrated approach. London: Marcel Dekker; 2004.
15. Brewerton TD, Frampton I, Lask B. The neurobiology of anorexia nervosa. US Psychiatry. 2009;2:57-64.
16. Kaye WH. Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa. Ann N Y Acad Sci. 1997;817:162-78. (Pubitemid 27344647)
17. Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Arch Gen Psychiatry. 1991;48:556-62.
18. Kaye W, Strober M, Stein D, Gendall K. New directions in treatment research of anorexia and bulimia nervosa. Biol Psychiatry. 1999;45:1285-92. (Pubitemid 29292504)
19. Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav. 2008;94:121-35. (Pubitemid 351506510)
20. Bailer UF, Price JC, Meltzer CC, et al. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacol. 2004;29:1143-55. (Pubitemid 38670051)
21. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Mathis CA, Wagner A, Thornton L, Hoge J, Ziolko SK, Becker CR, McConaha CW, Kaye WH. Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry. 2007;61:1090-9. (Pubitemid 46551971)
22. Galusca B, Costes N, Zito NG, et al. Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18 F]MPPF PET scan study. Biol Psychiatry. 2008;64:1009-13.
23. Audenaert K, Van Laere K, Dumont F, et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nuclear Med. 2003;44:163-9.
24. Goethals I, Vervaet M, Audenaert K, et al. Differences of cortical 5-HT2A receptor binding index with SPECT in subtypes of anorexia nervosa: relationship with personality traits? J Psychiatr Res. 2007;41:455-8. (Pubitemid 46187245)
25. Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Becker CR, Ziolko SK, Mathis CA, Wagner A, Barbarich-Marsteller NC, Putnam K, Kaye WH. Serotonin transporter binding after recovery from eating disorders. Psychopharmacol. 2007;195:315-24.
26. Ehrlich S, Franke L, Schott R, et al. Platelet monoamine oxidase activity in under weight and weight-recovered females with anorexia nervosa. Pharmacopsychiatry. 2008;41:226-31.
27. Gorwood P, Kipman A, Foulon C. The human genetics of anorexia nervosa. Eur J Pharmacol. 2003;480:163-70. (Pubitemid 37410368)
28. Rybakowski F, Slopien A, Dmitrzak-Weglarz M, et al. The 5-HT2A-1438 A/G and 5-HTTLPR polymorphisms and personality dimensions in adolescent anorexia nervosa: association study. Neuropsychobiology. 2006;53:33-9. (Pubitemid 43254175)
29. Kiezebrink K, Mann ET, Bujac SR, Stubbins MJ, Campbell DA, Blundell JE. Evidence of complex involvement of serotonergic genes with restrictive and binge purge subtypes of anorexia nervosa. World J Biol Psychiatry. 2010;11:824-33. This recent genetic study showed a substantial and complex inter-relationship between several serotoninergic genes and AN. HTR2A was associated with both AN subtypes, while genes encoding HTR1D and HTR1B were associated with anorexia nervosa, restricting type and the gene encoding HTR2C was associated with anorexia nervosa, binge-purge type. This study will help to guide future genetic research and also gives support for the use of atypical antipsychotics, such as olanzapine.
30. Bergen AW, van den Bree MB, Yeager M, et al. Candidate genes for anorexia nervosa in the 1p33-36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa. Mol Psychiatry. 2003;8:397-406. (Pubitemid 36609664)
31. Hu X, Giotakis O, Li T, et al. Association of the 5-HT2c gene with susceptibility and minimum body mass index in anorexia nervosa. Neuroreport. 2003;14:781-3. (Pubitemid 36667911)
32. Hammer C, Kapeller J, Endele M, et al. Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. Pharmacogenet Genom. 2009;19:790-9.
33. Martaskova D, Slachtova L, Kemlink D, et al. Polymorphisms in serotonin-related genes in anorexia nervosa. The first study in Czech population and metaanalyses with previously performed studies. Folia Biol. 2009;55:192-7.
34. Brown KM, Bujac SR, Mann ET, et al. Further evidence of association of OPRD1 & HTR1D polymorphisms with susceptibility to anorexia nervosa. Biol Psychiatry. 2007;61:367-73. (Pubitemid 46131428)
35. Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry. 2005;58:651-7. (Pubitemid 41565580)
36. Verhagen LA, Luijendijk MC, Hillebrand JJ, Adan RA. Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa. Eur Neuropsychopharmacol. 2009;19:153-60.
37. Wagner A, Aizenstein H, Venkatraman VK, et al. Altered reward processing in women recovered from anorexia nervosa. Am J Psychiatry. 2007;164:1842-9. (Pubitemid 351739237)
38. Bachner-Melman R, Lerer E, Zohar AH, et al. Anorexia nervosa, perfectionism, and dopamine D4 receptor (DRD4). Am J Med Genetics. 2007;144B:748-56. (Pubitemid 47417203)
39. Frank GK, Bailer UF, Henry SE, et al. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biol Psychiatry. 2005;58:908-12. (Pubitemid 41790720)
40. Frieling H, Romer KD, Scholz S, et al. Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat Disord. 2010;43:577-83.
41. Brandys MK, Kas MJ, van Elburg AA. A meta-analysis of circulating BDNF concentrations in anorexia nervosa. World J Biol Psychiatry. 2011;12:444-54. This study suggests that BDNF is not only an important indicator of illness and recovery but may also be a target for drug action in the treatment of AN. It is already known that atypical antipsychotics, especially olanzapine, increase BDNF levels.
42. Ehrlich S, Salbach-Andrae H, Eckart S, et al. Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa. J Psych Neurosci. 2009;34:323-9.
43. Mercader JM, Fernandez-Aranda F, Gratacos M, et al. Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients. Neuropsychobiology. 2007;56:185-90. (Pubitemid 351567535)
44. Monteleone P, Maj M. Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. Pharmacogenomics. 2008;9:1487-520.
45. Stahl SM. Describing an atypical antipsychotic: Receptor binding and its role in pathophysiology. J Clin Psychiatry. 2003;5 Suppl 3:9-13.
46. Rizos EN, Papadopoulou A, Laskos E, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2010;11:251-5.
47. Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychological effects. Int Clin Psychopharmacol. 2007;22:197-204. (Pubitemid 46801942)
48. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebocontrolled trial. Am J Psychiatry. 2008;165:1281-8. This is a very important randomized, placebo-controlled study that demonstrated olanzapine's ability to promote faster weight gain and alleviate obsessive symptoms in adult patients with AN who were receiving concurrent day treatment.
49. Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41:2177-82. This is a recent breakthrough study which showed that olanzapine significantly facilitates weight recovery in adult outpatients with AN in comparison to placebo. This was despite the absence of any adjunctive psychotherapy or behavior therapy during the trial.
50. Mondraty N, Birmingham CL, Touyz S, et al. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry. 2005;13:72-5. (Pubitemid 40514990)
51. Attia E, Kaplan AS, Schroeder L, Federici A. Atypical antipsychotic medication for patients with anorexia nervosa. Presented at the Annual Meeting of the Eating Disorders Research Society, Toronto, Canada, 2005.
52. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A doubleblind placebo-controlled cross-over study. Acta Psychiatr Scand. 1982;66:445-50. (Pubitemid 13242401)
53. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144:288-92. (Pubitemid 14159403)
54. Hagman J, Gralla J, Sigel E, et al. A double-blind, placebocontrolled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adol Psych. 2011;50:915-24. This is the only randomized, placebo-controlled study that has examined the role of risperidone in the treatment of AN -in this case, adolescent inpatients being treated in a specialized eating disorder service. Although there was no difference in weight gain, those receiving risperidone demonstrated significant improvements in interpersonal distrust compared with placebo.
55. Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adol Psychopharmacol. 2011;21:207-12. This recent randomized, placebo-controlled study examined the role of olanzapine in a group of adolescents being treated in a specialty eating disorder service. There was no statistically significant benefit of olanzapine for weight or psychological symptoms. Again, we see that olanzapine seems to primarily benefit individuals who are not receiving concurrent intensive treatment.